Finder makes money from featured partners, but editorial opinions are our own.

How to buy CSL (CSL) shares in Australia

Learn how to easily invest in CSL shares.

CSL (CSL) is an Australian biotechnology company that specialises in blood plasmas, vaccines and anti-venoms. The world's largest collector of blood plasmas, CSL is also one of Australia's 5 biggest companies by market capitalisation. In 2020, it agreed to manufacture the AstraZeneca COVID-19 vaccine for the Australian government.

How to buy shares in CSL

To buy shares listed in Australia such as CSL, you'll need to sign up to a broker with access to the ASX. Our table can help you compare share trading platforms and choose. Then follow these steps.

  1. Open and fund your brokerage account.
    Complete an application with your personal and financial details, including your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
  2. Search for CSL.
    Find the share by name or ticker symbol: CSL. Research its history to confirm it's a solid investment against your financial goals.
  3. Purchase now or later.
    Buy today with a market order or use a limit order to delay your purchase until CSL reaches your desired price. Look into dollar-cost averaging to spread out your risk, which smooths out buying at consistent intervals and amounts.
  4. Decide on how many to buy.
    At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
  5. Check on your investment.
    Congratulations, you own a part of CSL. Optimise your portfolio by tracking how your stock and the business performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that affect your stock.

CSL stock price (ASX:CSL)

Use our graph to track the performance of CSL stocks over time.

CSL shares at a glance

Information last updated 2024-02-13.
52-week range$228.65 - $310.6698
50-day moving average $287.0448
200-day moving average $273.0571
Target price$310.9
PE ratio 40.67
Dividend yield $2.36 (1.29%)
Earnings per share (TTM) $6.94

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
1 - 7 of 33
Name Product Standard brokerage fee Inactivity fee Asset class
eToro
Finder AwardExclusive
eToro
$0
US$10 per month if there’s been no log-in for 12 months
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get 12 months of investment tracking app Delta PRO for free when you fund your eToro account (T&Cs apply).
CFD service. Capital at risk.
Join the world's biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
Finder Award
IG Share Trading
$8
$0
ASX shares, Global shares, US shares, UK shares, ETFs
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian and international shares, plus get access to 24-hour customer support.
Moomoo Share Trading
$3
$0
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get an additional 30 days on top of the regular brokerage-free period for new accounts. T&Cs apply.
Trade shares on the ASX, the US markets and buy ETFs with Moomoo. Plus join a community over 20 million investors.
CMC Invest
Finder Award
CMC Invest
$0
$0
ASX shares, Global shares, Options trading, US shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 35,000 products, including shares, ETFs and managed funds, with access to 15 major global and Australian stock exchanges. Plus, buy Aussie shares for $0 brokerage up to $1,000. (Limited to one buy order per stock per trading day).
Webull
$4.90
$0
ASX shares, Options trading, US shares, ETFs
Fund your account with over $200 and complete 1 buy trade to earn $50 in free shares. Fund over $10,000 for up to $1,200 in trading vouchers, or over $100,000 for up to $4,000 in vouchers. Plus, enjoy 5.3% p.a. yield on US cash accounts with Moneybull (T&Cs apply).
Trade ASX and US stocks and US options, plus gain access to inbuilt news platforms and educational resources. You can also start trading for less with fractional shares.
Tiger Brokers
Exclusive
Tiger Brokers
$5.50
$0
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get 10 brokerage-free trades for the US or ASX market for the first 180 days and US$50 fractional shares when you deposit at least US$500. Plus, all new customers get 1 free trade per month for the first 12 months. Offer valid until February 29, 2024 (T&Cs apply).
Get one brokerage-free trade per month for the first 12 months for US or ASX markets. T&Cs apply.
Saxo Invested
$3
$0
ASX shares, Global shares, Options trading, US shares, ETFs
Access 22,000+ stocks on 50+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
loading

Is it a good time to buy CSL stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

CSL price performance over time

Historical closes compared with the last close of A$282.28

1 week (2024-02-13) 0.01%
1 month (2024-01-19) -2.33%
3 months (2023-11-21) 9.92%
6 months (2023-08-21) 5.78%
1 year (2023-02-21) -5.41%
2 years (2022-02-21) 7.11%
3 years (2021-02-19) 2.86%
5 years (2019-02-21) 52.17%

Is CSL under- or over-valued?

Valuing CSL stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of CSL's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

CSL's P/E ratio

CSL's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 41x. In other words, CSL shares trade at around 41x recent earnings.

That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

CSL's EBITDA

CSL's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.4 billion (£2.3 billion).

The EBITDA is a measure of a CSL's overall financial performance and is widely used to measure stock profitability.

CSL financials

Revenue TTM $14.2 billion
Operating margin TTM 32.45%
Gross profit TTM $6.8 billion
Return on assets TTM 6.41%
Return on equity TTM 13.63%
Profit margin 17.43%
Book value 35.601
Market capitalisation $136.4 billion

TTM: trailing 12 months

CSL's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like CSL.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

CSL's total ESG risk score

Total ESG risk: 27.73

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and CSL's overall score of 27.73 (as at 12/31/2018) is pretty good – landing it in it in the 40th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like CSL is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

CSL's environmental score

Environmental score: 3.04/100

CSL's environmental score of 3.04 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that CSL is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

CSL's social score

Social score: 18.57/100

CSL's social score of 18.57 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that CSL is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

CSL's governance score

Governance score: 11.12/100

CSL's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that CSL is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

CSL's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. CSL scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that CSL has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

CSL Ltd was last rated for ESG on: 2019-01-01.

Total ESG score 27.73
Total ESG percentile 39.7
Environmental score 3.04
Environmental score percentile 5
Social score 18.57
Social score percentile 5
Governance score 11.12
Governance score percentile 5
Level of controversy 2

CSL share dividends

51%

Dividend payout ratio: 50.65% of net profits

Recently CSL has paid out, on average, around 50.65% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.29% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), CSL shareholders could enjoy a 1.29% return on their shares, in the form of dividend payments. In CSL's case, that would currently equate to about A$2.36 per share.

CSL's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

The latest dividend was paid out to all shareholders who bought their shares by 10 September 2023 (the "ex-dividend date").

Have CSL's shares ever split?

CSL's shares were split on a 3:1 basis on 17 October 2007. So if you had owned 1 share the day before the split, the next day you would own 3 shares. This wouldn't directly have changed the overall worth of your CSL shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for CSL shares which in turn could have impacted CSL's share price.

CSL share price volatility

Over the last 12 months, CSL's shares have ranged in value from as little as $228.65 up to $310.6698. A popular way to gauge a stock's volatility is its "beta".

Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while CSL's is 0.295. This would suggest that CSL's shares are less volatile than average (for this exchange).

CSL overview

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Past developments

13 December 2022: Biotech giant CSL’s long-time CEO Paul Perreault will step down from his role in March after a decade at the helm. He will be replaced by current chief operating officer Paul McKenzie who joined CSL in 2019 after previous roles in Biogen, Johnson & Johnson and Merck.
12 January 2023: Citi analysts have put a “buy” rating on CSL shares and lifted their 12-month price target to $340, implying potential upside of 22% from current levels. The brokerage said CSL is set to benefit from improved trading conditions in the plasma industry as well as the recent acquisition of Vifor Pharma. It expects the company’s EPS to grow 20% in FY 2023, 23% in FY 2024 and 15.9% in FY 2025.

Frequently asked questions

  1. EOD price data and company information for CSL accessed 21 Feb 2024
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs comes with a higher risk of losing money rapidly due to leverage. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and 6. Finder Group Privacy & Cookies Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site